(Q40047397)

16 September 2017

title

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms (English)

1 reference

16 September 2017

1 reference

13

1 reference

16 September 2017

3

Michael Andreeff

1 reference

16 September 2017

Junya Kuroda

1

1 reference

16 September 2017

Shinya Kimura

2

1 reference

16 September 2017

Eishi Ashihara

4

1 reference

16 September 2017

Yuri Kamitsuji

5

1 reference

16 September 2017

Asumi Yokota

6

1 reference

16 September 2017

Eri Kawata

7

1 reference

16 September 2017

Miki Takeuchi

8

1 reference

16 September 2017

Ruriko Tanaka

9

1 reference

16 September 2017

Yoshihide Murotani

10

1 reference

16 September 2017

Yosuke Matsumoto

11

1 reference

16 September 2017

Hideo Tanaka

12

1 reference

16 September 2017

Masafumi Taniwaki

14

1 reference

16 September 2017

Taira Maekawa

15

1 reference

16 September 2017

language of work or name

English

0 references

publication date

20 November 2007

1 reference

British Journal of Haematology

16 September 2017

published in

1 reference

16 September 2017

volume

140

1 reference

16 September 2017

issue

2

1 reference

16 September 2017

page(s)

181-190

1 reference

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

The Bcl2 family: regulators of the cellular life-or-death switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Apoptosis-based therapies for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

Bcl-2 family proteins are essential for platelet survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06899.X

10.1111/J.1365-2141.2007.06899.X

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference